Risk and Benefit of apixaban treatment in thrombolysis in stroke
The study is focused on benefits and risks of apixaban use under thrombolytic treatment of ischemic stroke with alteplase since no medical guideline is available for this case. The apixaban impact on thrombolysis is studied in vitro as well as in vivo at FNUSA-ICRC, Institute of Biophysics and Institute of Scientific Instruments of the Czech Academy of Sciences.
The secondary objective is the estimation of safety (risk of hemorrhage) and the impact of apixaban on ischemia-reperfusion related events such as inflammatory damage of brain tissue.
Principal Investigator: prof. MUDr. Robert Mikulík, Ph.D.
Financed by: Pfizer – ERISTA grant program
Duration: 01.05.2018 – 31.12.2020